MUMBAI (Reuters) - The Delhi High Court on Monday granted U.S. pharmaceuticals giant Pfizer Inc's India unit a stay on a government ban on its popular cough syrup Corex, local television channels reported.
The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend ordering prohibition of the sale and manufacture of 344 combination drugs that a panel of experts found posed a risk to humans.
The next hearing by the Delhi High Court on Pfizer's plea is slated for March 21, TV channels said.
(Reporting by Zeba Siddiqui in MUMBAI; Editing by Gopakumar Warrier)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app